ClinicalTrials.gg
RecruitingNCT06662942LSUpdated Nov 8, 2024

StrataMGT in the Reduction of Vulvar Lichen Sclerosus (LS) Symptoms

A Phase 1 interventional study of StrataMGT and Placebo in Vulvar Lichen Sclerosus, sponsored by Andrew T. Goldstein, MD. Recruiting at 3 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Andrew T. Goldstein, MD · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Vulvar Lichen Sclerosus with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Vulvar Lichen Sclerosus · United States.

Planned enrollment
3rd of 12
100 · median 30
Started
2024
with 1 other
Phase 1
Only one
of the 13
Registered
11th of 13
by date
Lead sponsor
1 of 13
Andrew T. Goldstein, MD

Among the 13 studies in Vulvar Lichen Sclerosus with a site in United States, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 1, and was the 11th registered.

Vulvar Lichen Sclerosus

33 studies on the registry are indexed under Vulvar Lichen Sclerosus; 10 are open to participants now.

Browse Vulvar Lichen Sclerosus studies →

Open to participants now

4 of the 13 studies in Vulvar Lichen Sclerosus with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Vulvar Lichen Sclerosus studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Vulvar Lichen Sclerosus with a site in United States, or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy and safety of StrataMGT for the management of vulvar lichen sclerosus symptoms.

Read the detailed description

This will be a randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of StrataMGT for the management of the symptoms of vulvar lichen sclerosus. Up to 100 patients with a diagnosis of biopsy proven vulvar lichen sclerosus will be recruited from two centers. This study will consist of a two-week screening period and a 12-week treatment period. At the beginning of the screening period, a vulvoscopy will be performed at the screening visit and after the 12-week treatment period to rule out vulvar intrepithelial neoplasia (VIN) or carcinoma. All eligible patients will be randomized to receive either placebo gel or treatments with the investigation product, StrataMGT TM 1:1 ratio.

The primary efficacy endpoint will be change in score on the Vulvar Quality of Life Index 11 (VQLI).

Secondary efficacy endpoints will be the Skindex 29, and the Clinical Lichen Sclerosus Scoring Scale (CLISSCO).

All adverse events will be recorded, including serious adverse events. A physical examination will be performed at each visit.

03

Conditions studied

  • Vulvar Lichen Sclerosus

Keywords

  • StrataMGT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, 18 years or older.
  • With a diagnosis of proven vulvar lichen sclerosus.
  • Signed written .
  • Willingness and ability to comply with the study requirements.
  • Subject must have a score of 10 or greater in the VQLI at screening.
  • Must be on a stable regimen of topical or topical calcineurin inhibitor for at least 2 months prior to the screening visit.
  • Women currently on a stable regimen of intravaginal estrogen therapy for at least 2 months may remain on the estrogen therapy throughout the study.
  • Women currently using topical estrogen therapy on the vulva must stop two weeks prior to enrolling in the study.
  • Women must have a culture negative for candidiasis or bacterial vaginosis at screening.

Exclusion criteria

Exclusion Criteria:

  • Who are (e.g., lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have an uncontrolled malignant disease.
  • Who suffer from a topical or systemic infections (bacterial, viral or fungal) at the time of screening. Subjects who screen positive for either candidiasis or bacterial vaginosis at the screening visit may be treated and retested and may participate if the confirmatory test after treatment is negative. Any vulvovaginal infections during their participation in the study will be considered an adverse event. The subject will then stop the study IP and will be treated for the infection and may resume use of the IP 3 days after the last dose of medication for the infection. They will be discontinued from the study if they have two infections during the study.
  • Who have been diagnosed with lichen planus, psoriasis, intraepithelial neoplasia, or carcinoma of the vulva.
  • Who had received an drug within four weeks prior to the study or who intend to use other investigational drugs during the course of this study.
  • Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study.
  • Who have a history of substance abuse or any factor, which limits the subject's ability to cooperate with the study procedures.
  • Who are uncooperative, known to miss appointments (according to subjects' records) and are unlikely to follow medical instructions or are not willing to attend regularly scheduled visits.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Investigational product

    StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.

    Drug: StrataMGT

  • Placebo comparator
    Placebo

    This arm will be a sterile, transparent, water-soluble lubricating jelly that is not silicone-based.

    Drug: Placebo

Interventions

  • DrugStrataMGT

    StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.

  • DrugPlacebo

    The placebo is a sterile, transparent, water-soluble lubricating jelly that is not silicone-based. It will be applied topically to the vulvar skin.

06

What researchers measure

Primary outcomes

  1. Vulvar Quality of Life Index 11 (VQLI)

    The VQLI is used to "assess symptomatic, psychosexual and physical aspects of vulvar disease" \[1\] using the following scale: Very Much, A Lot, A Little, and Not At All. The questionnaire consists of 15 questions.

    Time frame: throughout the study, averaging 3.5 months

Secondary outcomes

  1. Skindex 29

    The Skindex 29 is a subjective survey used to assess which skin conditions have bothered a patient the most on the following scale: All the time, often, sometimes, rarely, and never. The survey consists of 30 questions.

    Time frame: throughout the study, averaging 3.5 months

  2. Clinical Scoring System for Vulvar Lichen Sclerosus

    The Clinical Scoring System for Vulvar Lichen Sclerosus is a subjective and objective survey filled out by the patient and provider. It is used to assess the patient's severity of subjective symptoms and the provider's interpretation of the severity of visible symptoms associated with vulvar LS.

    Time frame: throughout the study, averaging 3.5 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Oct 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2024
First posted
Oct 29, 2024
StartActual
Oct 16, 2024
Primary completionEst.
Oct 16, 2025
CompletionEst.
Oct 16, 2025
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06662942
Lead sponsor
Andrew T. Goldstein, MD
Collaborators
Stratpharma AG
Responsible party
Andrew T. Goldstein, MD (Principal Investigator, Center for Vulvovaginal Disorders) — Sponsor-investigator
First posted
Oct 29, 2024
Start date
Oct 16, 2024
Primary completion
Oct 16, 2025 (estimated)
Completion
Oct 16, 2025 (estimated)
Last update
Nov 8, 2024

Study contacts

Andrew T Goldstein, MD
Contact
obstetrics@yahoo.com
4102790209
Sylvia Lorenzini
Contact
sylvia@vulvodynia.com
Chailee Moss, MD
study director · Centers for Vulvovaginal Disorders, DC
Jill Krapf, MD
study director · Centers for Vulvovaginal Disorders, FL

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion